CDC: Lyme disease
CDC is currently conducting research to understand what concerns healthcare providers and the public may have about any potential Lyme disease vaccines. Once a Lyme disease vaccine is approved as safe and effective by the Food and Drug Administration (FDA), CDC will work with the Advisory Committee on Immunization Practices (ACIP) to develop recommendations about where in the U.S. the public might benefit from a Lyme disease vaccine. CDC will communicate these recommendations to increase awareness of a vaccine among the public and clinicians to prevent Lyme disease in the United States.
Valneva to study Lyme disease vaccine candidate in children
The study will include participants aged 5 to 65 years and will compare a reduced immunization schedule of two doses in 6 months with a three-dose, 6-month regimen…. The study — called VLA15-221 — will complement two ongoing phase 2 studies,VLA15-201 and VLA15-202, which have already reported positive data, Valneva said…. According to Valneva, all three phase 2 trials are anticipated to support a phase 3 pivotal efficacy trial, which will include all main target populations for the Lyme disease vaccine candidate starting in 2022.
Lyme Disease Vaccine Could Be Ready In 4 to 5 Years
“Phase 2 will end in the middle of 2020. We expect this will enable us to enter the last clinical phase in mid-2021,” explained [Valneva’s CEO, Thomas Lingelbach]. “Depending on those results, we may be four to four and a half years away from the first potential Lyme disease vaccine.”